Tumor-associated macrophages correlate with progesterone receptor loss in endometrial endometrioid adenocarcinoma. 2013

Xue-feng Jiang, and Qiong-lan Tang, and Hai-gang Li, and Xi-ming Shen, and Xin Luo, and Xiao-yu Wang, and Zhong-qiu Lin
Department of Obstetrics and Gynecology, First Affiliated Hospital of Jinan University, Guangzhou, China.

OBJECTIVE It has been well established that tumor-associated macrophages (TAMs) play a tumor promoting role in endometrial endometrioid adenocarcinoma (EEC). But the association with TAMs and sex hormone receptor expression, and progression of precancerous endometrial lesions in EEC has been little reported. METHODS We used immunohistochemistry to examine the expression of CD68, CD34, vascular endothelial growth factor (VEGF), estrogen receptor (ER) and progesterone receptor (PR) in 95 cases of EEC, as well as 35 cases of endometrial hyperplasia (including 15 atypical hyperplasia, 10 complex hyperplasia and 10 simple hyperplasia). We also correlated TAMs count with various clinicopathological factors, sex hormone receptor, and prognostic value in patients with EEC. RESULTS We identified that TAMs count increased linearly with disease progression (mean count per case at × 200 magnification: simple hyperplasia, 6.30; complex hyperplasia, 11.20; atypical hyperplasia, 29.40; EEC 55.81, respectively; P < 0.001), that microvascular density (MVD) also increased accordingly (27.50, 30.20, 50.13 and 59.94, respectively; P < 0.001). The expression of progesterone receptor, not of estrogen receptor, significantly decreased with disease progression (P < 0.05). Moreover, histopathologic grades, International Federation of Gynecology and Obstetrics (FIGO) stage (2009), depth of myometrial invasion, pelvic lymph node metastasis, lymphovascular space invasion, and expression of PR and VEGF were associated with TAMs count (P = 0.0001, P = 0.004, P = 0.0001, P = 0.04, P = 0.0001, P = 0.0001, P = 0.0001, respectively). Progesterone receptor expression was also associated with histopathologic grades, lymphovascular space invasion, VEGF and high TAMs (P = 0.035, P = 0.022, P = 0.014, P = 0.001, respectively). The estimated 5-year survival rate of patients with low TAMs was significantly higher than those with high TAMs (96.4% vs 69.8%, P = 0.002). CONCLUSIONS TAMs are potentially related to PR loss and progression of precancerous endometrial lesions in EEC.

UI MeSH Term Description Entries
D008264 Macrophages The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.) Bone Marrow-Derived Macrophages,Monocyte-Derived Macrophages,Macrophage,Macrophages, Monocyte-Derived,Bone Marrow Derived Macrophages,Bone Marrow-Derived Macrophage,Macrophage, Bone Marrow-Derived,Macrophage, Monocyte-Derived,Macrophages, Bone Marrow-Derived,Macrophages, Monocyte Derived,Monocyte Derived Macrophages,Monocyte-Derived Macrophage
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D011230 Precancerous Conditions Pathological conditions that tend eventually to become malignant. Preneoplastic Conditions,Condition, Preneoplastic,Conditions, Preneoplastic,Preneoplastic Condition,Condition, Precancerous,Conditions, Precancerous,Precancerous Condition
D011980 Receptors, Progesterone Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives. Progesterone Receptors,Progestin Receptor,Progestin Receptors,Receptor, Progesterone,Receptors, Progestin,Progesterone Receptor,Receptor, Progestin
D004714 Endometrial Hyperplasia Benign proliferation of the ENDOMETRIUM in the UTERUS. Endometrial hyperplasia is classified by its cytology and glandular tissue. There are simple, complex (adenomatous without atypia), and atypical hyperplasia representing also the ascending risk of becoming malignant. Atypical Endometrial Hyperplasia,Complex Endometrial Hyperplasia,Simple Endometrial Hyperplasia,Atypical Endometrial Hyperplasias,Complex Endometrial Hyperplasias,Endometrial Hyperplasia, Atypical,Endometrial Hyperplasia, Complex,Endometrial Hyperplasia, Simple,Endometrial Hyperplasias,Endometrial Hyperplasias, Atypical,Endometrial Hyperplasias, Complex,Endometrial Hyperplasias, Simple,Hyperplasia, Atypical Endometrial,Hyperplasia, Complex Endometrial,Hyperplasia, Endometrial,Hyperplasia, Simple Endometrial,Hyperplasias, Atypical Endometrial,Hyperplasias, Complex Endometrial,Hyperplasias, Endometrial,Hyperplasias, Simple Endometrial,Simple Endometrial Hyperplasias
D004717 Endometrium The mucous membrane lining of the uterine cavity that is hormonally responsive during the MENSTRUAL CYCLE and PREGNANCY. The endometrium undergoes cyclic changes that characterize MENSTRUATION. After successful FERTILIZATION, it serves to sustain the developing embryo. Endometria
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Xue-feng Jiang, and Qiong-lan Tang, and Hai-gang Li, and Xi-ming Shen, and Xin Luo, and Xiao-yu Wang, and Zhong-qiu Lin
August 2015, Gynecologic oncology reports,
Xue-feng Jiang, and Qiong-lan Tang, and Hai-gang Li, and Xi-ming Shen, and Xin Luo, and Xiao-yu Wang, and Zhong-qiu Lin
November 2014, Gynecologic oncology,
Xue-feng Jiang, and Qiong-lan Tang, and Hai-gang Li, and Xi-ming Shen, and Xin Luo, and Xiao-yu Wang, and Zhong-qiu Lin
January 2005, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
Xue-feng Jiang, and Qiong-lan Tang, and Hai-gang Li, and Xi-ming Shen, and Xin Luo, and Xiao-yu Wang, and Zhong-qiu Lin
October 2011, Archives of gynecology and obstetrics,
Xue-feng Jiang, and Qiong-lan Tang, and Hai-gang Li, and Xi-ming Shen, and Xin Luo, and Xiao-yu Wang, and Zhong-qiu Lin
September 2013, Gynecologic oncology,
Xue-feng Jiang, and Qiong-lan Tang, and Hai-gang Li, and Xi-ming Shen, and Xin Luo, and Xiao-yu Wang, and Zhong-qiu Lin
October 2006, The journal of obstetrics and gynaecology research,
Xue-feng Jiang, and Qiong-lan Tang, and Hai-gang Li, and Xi-ming Shen, and Xin Luo, and Xiao-yu Wang, and Zhong-qiu Lin
July 2018, Mayo Clinic proceedings,
Xue-feng Jiang, and Qiong-lan Tang, and Hai-gang Li, and Xi-ming Shen, and Xin Luo, and Xiao-yu Wang, and Zhong-qiu Lin
April 1997, The American journal of surgical pathology,
Xue-feng Jiang, and Qiong-lan Tang, and Hai-gang Li, and Xi-ming Shen, and Xin Luo, and Xiao-yu Wang, and Zhong-qiu Lin
April 2008, Gynecologic oncology,
Xue-feng Jiang, and Qiong-lan Tang, and Hai-gang Li, and Xi-ming Shen, and Xin Luo, and Xiao-yu Wang, and Zhong-qiu Lin
March 2023, Applied immunohistochemistry & molecular morphology : AIMM,
Copied contents to your clipboard!